日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

非对称抗 CLL-1×CD3 双特异性抗体 ABL602 2+1 具有减弱的 CD3 亲和力,具有强大的抗肿瘤活性,但细胞因子释放有限

Eunhee Lee, Shinai Lee, Sumyeong Park, Yong-Gyu Son, Jiseon Yoo, Youngil Koh, Dong-Yeop Shin, Yangmi Lim, Jonghwa Won

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

新型抗4-1BB×PD-L1双特异性抗体通过肿瘤导向的T细胞活化和检查点阻断增强抗肿瘤免疫力

Seongju Jeong ,Eunyoung Park ,Hyung-Don Kim ,Eunsil Sung ,Hyunjoo Kim ,Jaehyoung Jeon ,Youngkwang Kim ,Ui-Jung Jung ,Yong-Gyu Son ,Youngeun Hong ,Hanbyul Lee ,Shinai Lee ,Yangmi Lim ,Jonghwa Won ,Minwoo Jeon ,Shin Hwang ,Lei Fang ,Wenqing Jiang ,Zhengyi Wang ,Eui-Cheol Shin ,Su-Hyung Park ,Jaeho Jung

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.

一种用于治疗间皮素阳性实体瘤的新型T细胞结合双特异性抗体

Yoon Aerin, Lee Shinai, Lee Sua, Lim Sojung, Park Yong-Yea, Song Eunjung, Kim Dong-Sik, Kim Kisu, Lim Yangmi